A Randomized Double-Blind Placebo-Controlled. Multi-center Proof-of-Mechanism Phase 2a Study to Evaluate the Safety Tolerability and efficacy of TAK-018 (EB8018) for the Prevention of Post-Operative Crohn s Disease Recurrence.

Brief description of study

The main purpose of this study is to evaluate how safe and tolerable a drug called TAK-018 (or sibofimloc,the “Takeda Study Drug”) is in people with Crohn’s disease (CD) after bowel resection. The study will also look at whether TAK-018 can stop CD from recurring after surgery. TAK-018 is an investigational drug. “Investigational” means that the study drug being tested has not yet been approved by the United States Food and Drug Administration (FDA). TAK-018 is a tablet which is taken orally (by mouth).

Clinical Study Identifier: s19-00438
ClinicalTrials.gov Identifier: NCT03709628
Principal Investigator: Jordan E Axelrad.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.